We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Altimmune, Inc. (ALT - Free Report) . Shares have added about 14.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Altimmune due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Altimmune’s Q2 Loss Narrower Than Expected, Revenues Nil
Altimmune incurred a second-quarter 2026 loss of 12 cents per share, narrower than the Zacks Consensus Estimate of a loss of 15 cents. The company had recorded a loss of 27 cents per share in the year-ago quarter.
The company did not generate any revenues in the quarter, as it does not have a marketed drug in its portfolio.
ALT's Q2 Results in Detail
Research and development (R&D) expenses totaled $18.7 million in the reported quarter, up 8.2% year over year, primarily due to ongoing clinical studies and startup costs associated with the late-stage metabolic dysfunction-associated steatohepatitis (MASH) study onpemvidutide. R&D spending included $11.6 million in direct pemvidutide development costs.
General and administrative expenses were $7.6 million, up 33.1% year over year, primarily driven by an increase in professional services and compensation expenses.
As of June 30, 2026, Altimmune had cash, cash equivalents and short-term investments of $519 million compared with $332 million as of March 31, 2026. Management expects its cash runway to support operations into 2029.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 11.29% due to these changes.
VGM Scores
Currently, Altimmune has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Altimmune has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Altimmune belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR - Free Report) , has gained 0.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
United Therapeutics reported revenues of $783.3 million in the last reported quarter, representing a year-over-year change of -1.9%. EPS of $7.27 for the same period compares with $6.41 a year ago.
For the current quarter, United Therapeutics is expected to post earnings of $6.47 per share, indicating a change of -9.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Altimmune, Inc. (ALT - Free Report) . Shares have added about 14.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Altimmune due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Altimmune’s Q2 Loss Narrower Than Expected, Revenues Nil
Altimmune incurred a second-quarter 2026 loss of 12 cents per share, narrower than the Zacks Consensus Estimate of a loss of 15 cents. The company had recorded a loss of 27 cents per share in the year-ago quarter.
The company did not generate any revenues in the quarter, as it does not have a marketed drug in its portfolio.
ALT's Q2 Results in Detail
Research and development (R&D) expenses totaled $18.7 million in the reported quarter, up 8.2% year over year, primarily due to ongoing clinical studies and startup costs associated with the late-stage metabolic dysfunction-associated steatohepatitis (MASH) study onpemvidutide. R&D spending included $11.6 million in direct pemvidutide development costs.
General and administrative expenses were $7.6 million, up 33.1% year over year, primarily driven by an increase in professional services and compensation expenses.
As of June 30, 2026, Altimmune had cash, cash equivalents and short-term investments of $519 million compared with $332 million as of March 31, 2026. Management expects its cash runway to support operations into 2029.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 11.29% due to these changes.
VGM Scores
Currently, Altimmune has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Altimmune has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Altimmune belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR - Free Report) , has gained 0.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
United Therapeutics reported revenues of $783.3 million in the last reported quarter, representing a year-over-year change of -1.9%. EPS of $7.27 for the same period compares with $6.41 a year ago.
For the current quarter, United Therapeutics is expected to post earnings of $6.47 per share, indicating a change of -9.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.